Robert J Jones

Professor Robert J Jones is a Professor of Clinical Cancer Research at the University of Glasgow, affiliated with the Clinical Research Gartnavel and the Beatson West of Scotland Cancer Centre. His research primarily focuses on urological cancers (prostate, bladder, and kidney) and colorectal/lower gastrointestinal cancers, with particular interest in the gut microbiome's role in cancer.

Professor Jones maintains an active research program with over 160 publications spanning two decades, with recent work (2023-2025) emphasizing cardiovascular toxicities of cancer therapies, novel prostate cancer treatments, and real-world evidence studies for urological malignancies. His research bridges laboratory discoveries with clinical applications through extensive involvement in national and international clinical trials.

Key research themes include:

• Cardiovascular effects of targeted cancer therapies (BRAF/MEK inhibitors, VEGF inhibitors)
• Novel treatment combinations for advanced prostate cancer (AKT inhibitors, PARP inhibitors)
• Real-world outcomes analysis for urological cancers using NHS data
• Patient representation in clinical trials, particularly for those with comorbidities
• Economic evaluation of novel cancer treatments within healthcare systems

Professor Jones has made significant contributions to major clinical trials including the POUT trial for upper tract urothelial cancer and the TALAPRO-2 trial for prostate cancer. His work on cardiovascular toxicities has directly influenced clinical monitoring protocols for patients receiving targeted cancer therapies. He actively collaborates with multidisciplinary teams across the UK and internationally to advance evidence-based cancer care.

His innovative work extends to patient and public involvement (PPI) in cancer research, exploring creative approaches to integrate patient perspectives into study design. With an ORCID profile (0000-0002-2904-6980) documenting sustained scholarly contributions, Professor Jones remains a leading figure in translational oncology research with direct impact on clinical practice guidelines.